Glenmark receives ANDA approval for Deferasirox Tablets
07 January 2020 | News
It is the generic version of Exjade® Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, of Novartis Pharmaceuticals Corporation
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, the generic version of Exjade® Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, of Novartis Pharmaceuticals Corporation.
According to IQVIATM sales data for the 12‐month period ending November 2019, the Exjade® Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg market2 achieved annual sales of approximately $106.4 million.
Glenmark’s current portfolio consists of 165 products authorized for distribution in the U.S. marketplace and 43 ANDA’s pending approval with the U.S. FDA.
